ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

patent: 4 patents

Readers on

mendeley: 4 Mendeley

Summary Patents

So far, Altmetric has seen 4 patents that reference this research output.

Agonistic antibodies that bind human CD40 and uses thereof

N/A CN-109071665-B

China

ANTIBODIES

Application EP-3552665-A3

European Patent Office

AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF

Application WO-2017184619-A3

World Intellectual Property Organisation (WIPO)

COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES

Application WO-2016023960-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.